This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit

Company Overview - Arcutis Biotherapeutics specializes in developing topical therapies for chronic skin conditions, focusing on psoriasis and atopic dermatitis [1][5] - The company generates revenue through proprietary dermatology treatments, primarily targeting prescription-based therapies for chronic inflammatory skin disorders [8] Recent Developments - Tejara Capital sold its entire holding of 520,503 shares in Arcutis Biotherapeutics, resulting in a decrease of $9.81 million in value [2][3] - This sale reduced Tejara Capital's position in Arcutis from 5.1% of assets under management (AUM) to zero [3] Financial Performance - As of February 4, shares of Arcutis Biotherapeutics were priced at $26.08, reflecting a 99.1% increase over the past year, significantly outperforming the S&P 500's 14% gain [3] - The company reported net product revenue of $99.2 million in the third quarter, more than doubling year over year, with management projecting full-year 2026 net product sales of approximately $455 million to $470 million [9] Market Position - Arcutis Biotherapeutics has transitioned into a revenue-scale phase, where sustained prescription growth and operational efficiency are critical for future returns [10] - The company’s lead products include roflumilast cream for plaque psoriasis and atopic dermatitis, with a focus on expanding its market presence [8]